Cargando…

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond

Detalles Bibliográficos
Autores principales:	Chen, Lanyi Nora, Carvajal, Richard D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477649/ https://www.ncbi.nlm.nih.gov/pubmed/37675306 http://dx.doi.org/10.21037/atm-23-839

Ejemplares similares

KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma
por: Pandey, Abhishek
Publicado: (2022)

KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Translating KEYNOTE-048 into practice recommendations for head and neck cancer
por: Szturz, Petr, et al.
Publicado: (2020)

KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study
por: Gómez-Randulfe, Igor, et al.
Publicado: (2023)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Beyond the trends: policy considerations in psychiatric rehabilitation
por: Goldman, Howard H, et al.
Publicado: (2012)

The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer
por: Wang, Yanye, et al.
Publicado: (2020)

Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden
por: Egger, Michael E.
Publicado: (2023)

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020)

Considering adjuvant therapy for stage II melanoma
por: Poklepovic, Andrew S., et al.
Publicado: (2019)

Keynotes
Publicado: (2023)

Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastases
por: Rutkowski, Piotr, et al.
Publicado: (2023)

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
por: Russo, Alessandro, et al.
Publicado: (2019)

The age of enlightenment in melanoma immunotherapy
por: Albertini, Mark R.
Publicado: (2018)

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
por: de Silva, Madhawa, et al.
Publicado: (2020)

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
por: Livingstone, Ann, et al.
Publicado: (2021)

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
por: Hamid, Omid, et al.
Publicado: (2021)

CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?
por: Su, David, et al.
Publicado: (2023)

Keynote Address
por: Zinsou, Lionel
Publicado: (2019)

Keynote Address
por: Cherkaoui El Moursli, Rajaa
Publicado: (2019)

Keynote Address
por: Schönenberger, Klaus
Publicado: (2019)

Welcome & Keynote
por: Martin, Robert "Uncle Bob"
Publicado: (2019)

Keynote Address
por: Bordry, Frederick
Publicado: (2019)

Keynote presentations
por: Desai, Nitin, et al.
Publicado: (2004)

Keynote Lectures
Publicado: (2004)

Keynote Lecture
Publicado: (2017)

KEYNOTE ADDRESS
por: Fenner, Frank
Publicado: (1986)

Keynote Symposium
Publicado: (2022)

Keynote 1
Publicado: (2022)

Keynote 4
Publicado: (2022)

Keynote 2
Publicado: (2022)

Keynote 3
Publicado: (2022)

Melanoma immunotherapy
por: Garg, Abhishek D., et al.
Publicado: (2015)

What can we learn from phase II adjuvant trials in melanoma?
por: Keilholz, U, et al.
Publicado: (2000)

Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
por: Sano, Daisuke, et al.
Publicado: (2023)

Characterization of the tumor microenvironment by single-cell RNA sequencing in non-small cell lung cancer treated with neo-adjuvant immunotherapy
por: Nagl, Laurenz, et al.
Publicado: (2023)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_nhn6rhh1el2bj0u1dlgif78ca2